文献速递肝病

他汀类药物:老药治疗肝病的新疗法?

Statins: Old drugs as new therapy for liver diseases?
PubMed 文献 · J Hepatol · 2018-08-01

他汀类药物除降胆固醇外,还具有抗炎、抗血管生成和抗纤维化等多效性,可能对某些慢性炎症性疾病有益。由于对肝功能受损患者安全性的担忧,近年才研究其作为慢性肝病潜在治疗选择;动物实验显示他汀可减轻肝脏炎症、纤维生成和门静脉压力。

要点

  • 动物实验显示他汀可减轻肝脏炎症、纤维生成和门静脉压力。
  • 回顾性队列研究显示他汀治疗与肝硬化及肝硬化前疾病患者疾病进展、肝功能失代偿、肝细胞癌发生和死亡风险降低相关。
  • 少数随机对照试验显示辛伐他汀可降低门静脉压力(两项研究)和死亡率(一项研究)。

核心结论

  • 他汀治疗通常耐受良好,但少数患者出现严重副作用,尤其是横纹肌溶解。
  • 尽管有这些有希望的有益效果,在推荐他汀用于临床实践之前,应在大系列患者中进行进一步随机对照试验,以硬临床终点为评价指标。

研究设计与样本

  • 综述总结了动物模型实验研究、大型人群回顾性队列研究以及少数随机对照试验的证据。

主要发现

  • 动物肝病模型实验研究显示他汀降低肝脏炎症、纤维生成和门静脉压力。
  • 肝硬化及肝硬化前疾病大型人群回顾性队列研究显示,以降低高胆固醇水平为目的的他汀治疗与疾病进展、肝功能失代偿、肝细胞癌发生和死亡风险降低相关。
  • 调整疾病严重程度和其他潜在混杂因素后,这些有益效果持续存在。
  • 少数随机对照试验显示辛伐他汀降低门静脉压力(两项研究)和死亡率(一项研究)。
  • 他汀治疗通常耐受良好,但少数患者出现严重副作用,尤其是横纹肌溶解。

关键数值与推荐

  • 随机对照试验显示辛伐他汀降低门静脉压力(两项研究)和死亡率(一项研究)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在推荐他汀用于临床实践之前,应在大系列患者中进行进一步随机对照试验,以硬临床终点为评价指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large populations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins, with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial effects persisted after adjustment for disease severity and other potential confounders. Finally, a few randomised controlled trials have shown that treatment with simvastatin decreases portal pressure (two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects, further randomised controlled trials in large series of patients with hard clinical endpoints should be performed before statins can be recommended for use in clinical practice.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Pose E, Trebicka J, Mookerjee RP, et al. Statins: Old drugs as new therapy for liver diseases? J Hepatol. 2018. PMID: 30075229. doi:10.1016/j.jhep.2018.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。